Tiwari et al., 2018 - Google Patents
Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infectionTiwari et al., 2018
View HTML- Document ID
- 10536364311374828139
- Author
- Tiwari P
- Vanover D
- Lindsay K
- Bawage S
- Kirschman J
- Bhosle S
- Lifland A
- Zurla C
- Santangelo P
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
The lung is a critical prophylaxis target for clinically important infectious agents, including human respiratory syncytial virus (RSV) and influenza. Here, we develop a modular, synthetic mRNA-based approach to express neutralizing antibodies directly in the lung via …
- 102000004965 antibodies 0 title abstract description 72
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48776—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tiwari et al. | Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection | |
| López-Muñoz et al. | Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity | |
| Ngo et al. | Identifying cell receptors for the nanoparticle protein corona using genome screens | |
| Jain et al. | Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery | |
| Yin et al. | Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers | |
| Pulford et al. | Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures | |
| US20240247265A1 (en) | Constructs and methods for preparing circular rna | |
| Jayasinghe et al. | Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy | |
| Tai et al. | A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection | |
| JP2023527556A (en) | Engineered coronavirus spike (S) proteins and methods of their use | |
| Ma et al. | The low-density lipoprotein receptor promotes infection of multiple encephalitic alphaviruses | |
| CN120500349A (en) | Compositions comprising antibody cleaving enzymes and methods of use thereof | |
| Sun et al. | Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants | |
| He et al. | The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis | |
| Marcos-Villar et al. | Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium | |
| Zeng et al. | Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine against Mycoplasma pneumoniae infection in BALB/c mice | |
| CN119563038A (en) | Compositions and methods for modulating immune responses | |
| Sánchez Romano et al. | Liver sinusoidal cells eliminate blood-borne phage K1F | |
| US20230218746A1 (en) | Compositions and methods relating to antiviral therapeutics | |
| US20250195684A1 (en) | Delivery methods using platelets | |
| Lee et al. | Therapeutic strategy for the prevention of pseudorabies virus infection in C57BL/6 mice by 3D8 scFv with intrinsic nuclease activity | |
| Fan et al. | Screening and identification of nucleocapsid protein-nanobodies that inhibited Newcastle disease virus replication in DF-1 cells | |
| CN113975299B (en) | Method for preventing and treating respiratory infectious diseases by utilizing respiratory epithelial cell membrane and application thereof | |
| WO2023069971A2 (en) | Cd24-loaded vesicles for treatment of cytokine storm and other conditions | |
| Marzolini et al. | Targeting DNA-LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity |